Study of BMS-663513 in Patients With Advanced Cancer

Update Il y a 4 ans
Reference: NCT00309023

Woman and Man

Extract

This is a Phase I/II, ascending, multi-dose study of BMS-663513, an agonistic anti-CD137 monoclonal antibody, administered every three weeks to patients with metastatic or locally advanced solid tumors.


Inclusion criteria

  • Tumors

Links